Should Shareholders Reconsider iTeos Therapeutics, Inc.'s (NASDAQ:ITOS) CEO Compensation Package? [Yahoo! Finance]
iTeos Therapeutics, Inc. (ITOS)
Company Research
Source: Yahoo! Finance
Total compensation is 38% above industry average iTeos Therapeutics' three-year loss to shareholders was 17% while its EPS was down 40% over the past three years Shareholders will probably not be too impressed with the underwhelming results at iTeos Therapeutics, Inc. NASDAQ:ITOS ) recently. Shareholders will be interested in what the board will have to say about turning performance around at the next AGM on 11th of June. It would also be an opportunity for shareholders to influence management through voting on company resolutions such as executive remuneration, which could impact the firm significantly. The data we present below explains why we think CEO compensation is not consistent with recent performance. View our latest analysis for iTeos Therapeutics Comparing iTeos Therapeutics, Inc.'s CEO Compensation With The Industry At the time of writing, our data shows that iTeos Therapeutics, Inc. has a market capitalization of US$633m, and reported total annual CEO compensat
Show less
Read more
Impact Snapshot
Event Time:
ITOS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ITOS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ITOS alerts
High impacting iTeos Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ITOS
News
- iTeos Therapeutics and GSK begin Phase III trial of combination therapy for NSCLC [Yahoo! Finance]Yahoo! Finance
- iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $21.00 price target on the stock.MarketBeat
- iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer [Yahoo! Finance]Yahoo! Finance
- iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung CancerGlobeNewswire
- iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its price target raised by analysts at HC Wainwright from $44.00 to $46.00. They now have a "buy" rating on the stock.MarketBeat
ITOS
Earnings
- 5/10/24 - Miss
ITOS
Sec Filings
- 6/13/24 - Form 4
- 6/13/24 - Form 4
- 6/13/24 - Form 4
- ITOS's page on the SEC website